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Ocular Neurosyphilis as First Manifestation of Infection in a
non-immunosuppressed patient
Louisa Bauer, B.S.1, Jacques Reynolds, D.O.2
1 Tufts University School of Medicine - Maine Medical Center, Portland, ME, 2 Neurology, Mid Coast Medical Group

Introduction

Ophthalmologic Imaging

Discussion

Syphilis is a sexually transmitted infection caused by spirochete Treponema
pallidum. In 2018, combined cases of syphilis, gonorrhea, and chlamydia hit an
all-time high. 35,000 cases of primary and secondary syphilis were reported in
the U.S. in 2018, representing a 14% increase from 2017.

Case
History of Present Illness:
59-year-old male presents to his primary care provider with 5 days of visual
disturbances in the left eye. He describes episodes of cloudiness, appearance of
blue strings of lights (photopsia), and tunnel vision only in the left eye. These
episodes last only seconds and occur intermittently throughout the day. He
denies headache, pain with extraocular movements, vision loss, dizziness, or
history of similar episodes. Earlier in the year, his blood pressure was poorly
controlled, but is currently well-controlled on lisinopril. His PCP placed an
urgent ophthalmology referral due to concern for retinal detachment.
Funduscopic exam reveals a pale, swollen optic disc in the L eye with
peripapillary venous congestion and a preserved physiologic cup (Figure 1A).
Retinal imaging called Optical Coherence Tomography (OCT) shows retinal nerve
fiber layer (NFL) edema OU, but worse in left eye. Due to concern for ischemic
optic neuropathy due to Temporal Arteritis, his ophthalmologist orders a
CRP/ESR. CRP 1.7 mg/dL and ESR 40 mm/hr, both mildly elevated. He
immediately starts 80mg prednisone daily and is sent for temporal artery biopsy
3 days later. Tunnel vision improves, but he still sees ‘wavy blue lines’ and has
an intermittent ‘blurred spot’ in his vision. Temporal artery biopsy is negative.
2-week follow-up with ophthalmology. Although symptoms improved, his visual
field testing is worse in the left eye and OCT shows worsening NFL edema in
both eyes (Figure 1B). Given worsening inflammation despite high-dose steroids,
ophthalmologist recommends emergent brain MRI and Neurology consult.
PMH: HTN, HLD, migraines, anxiety, benign prostatic hypertrophy
SH: Never smoker. Does not drink alcohol or use recreational drugs. He is
widowed and lives alone. Currently does not have health insurance.
FH: Father had HTN. Mother had COPD and T2DM. Sister has T2DM.
Medications: Lisinopril-HCTZ, Loratadine, Tamsulosin, Excedrin migraine,
Tadalafil, Alprazolam PRN
Allergies: None

Physical Exam:
Vitals: Temp 37˚C, BP 102/70, Heart rate 116 at first outpatient visit
GEN: Awake, alert, oriented, well appearing. In NAD.
HEENT: Sclerae anicteric. Conjunctivae noninjected. No discharge.
Neck: No lymphadenopathy, masses, or thyromegaly. No JVD. No neck stiffness.
CV: +S1/S2. Tachycardic. Regular rhythm. No murmurs, rubs, or gallops.
Neurologic: Visual acuity grossly intact. PERRLA, EOMI, no afferent pupillary
defect. Strength, sensation, reflexes intact. Normal gait. CN II-XII intact.
https://knowledgeconnection.mainehealth.org/jmmc/vol3/iss1/14
DOI: 10.46804/2641-2225.1080
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Figure 1. Optical coherence tomography (OCT) using Spectralis Tracking Laser Tomography. The top images represent the retina and the bottom images represent a cross section of the retina with the optic nerve
in the middle. A) 11/26/2019 first visit to ophthalmologist. B) 12/10/2019 follow-up after 8 days of high-dose prednisone. C) 1/28/2020 follow-up 3 weeks after completing IV Penicillin treatment.

Hospital Course and Treatment
•
•
•
•
•
•
•
•

15 days after initial visit, presents to ER for workup & Neurology consult
MRI brain w/o gadolinium: No significant abnormality
MRI/MRA/MRV head w/ gadolinium: No significant abnormality.
Lumbar puncture: Traumatic tap. Difficult to interpret initially; the
traumatic tap may account for elevated WBC and protein.
7 days later, develops ringing in both ears and new headache.
RPR, Treponemal EIA, and CSF VDRL are positive, suggesting neurosyphilis
4 weeks after initial visit, he is admitted for 2 days of IV Penicillin G 5
million units Q4 hours, then discharged with midline to receive 20 million
units by continuous infusion for total 14-day course.
3-week follow-up: Auditory disturbance resolved promptly. Vision
gradually improving since treatment. Retinal imaging shows marked
improvement (Fig 1). He will continue follow-up with serial RPRs.

Laboratory Findings
87% PMNs
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CSF Studies (traumatic tap):
• Glucose: 66 mg/dL (nl 50-80)
• Protein: 82 mg/dL (15-45)
• RBC: 11,000/mm3 tube 4 (14,000 tube1)
• WBC: 24/mm3, 53% PMNs, 47% Monos
(corrected for RBCs: 23.95)
• Gram stain: 1+ PMNs, no growth
• EBV PCR (-); HSV DNA: Not detected
• ACE CSF <0.4 (normal)
• 0 CSF Oligoclonal bands seen
• CSF VDRL titer 1:2 (Low positive)

44
1.06

137

LFTs normal
CRP: 1.7 (< 1)
ESR: 40 (0-20)

Other Blood tests:
• Lyme Ab Scrn (+); Confirmatory
Western blot (-)
• Quantiferon Gold (-), HIV1/2 (-),
ACE: <5 (normal)
• Neuromyelitis Optica/AQP4 FACS
negative
• RPR Screen: Reactive
• RPR Titer: 1:128
• Syphilis IgG (Treponemal EIA):
Positive

Testing Algorithms for Syphilis
Testing for Syphilis Infection
•Darkfield microscopy and PCR are definitive tests, but
infrequently used as they are difficult to perform
•Presumptive diagnosis requires: Nontreponemal test
(Venereal Disease Research Laboratory (VDRL) or Rapid
Plasma Reagin (RPR)) + Treponemal Test (i.e. Fluorescent
treponemal antibody absorbed (FTA-ABS), T. pallidum
passive particle agglutination (TP-PA) assay, enzyme
immunoassays (EIAs))
• Nontreponemal tests have high false-positive rates
and are associated with many other medical
conditions
•Traditional Screening Algorithm: Screen with
Nontreponemal test -> if positive, confirm with Treponemal
test
•Reverse Screening Algorithm: Screen with Treponemal test
to determine if patient has ever been exposed to T.
pallidum -> if positive, follow with Nontreponemal test to
determine if patient has active infection
Further testing for Neurosyphilis
•CSF VDRL preferred test, highly specific but not sensitive
• False-positives can be due to contamination with
peripheral blood
• False-negative may occur in >25% of patients
•CSF WBC often elevated with lymphocytic predominance
•Fluorescent treponemal antibody absorption (FTA-ABS) is
sensitive, but less specific test
•Serum RPR titer ≥ 1:32 is associated with increased
likelihood of neurosyphilis in patients with syphilis infection

Clinical Presentation
• Syphilis can present in 3 stages, often with periods of latency (no
symptoms, but positive serologies) in between:
• Primary: painless chancre at site of transmission
• Secondary: development of systemic symptoms including fever,
lymphadenopathy, skin rash, mucocutaneous lesions
• Tertiary: gummatous disease, tabes dorsalis, cardiovascular disease
• Neurosyphilis and Ocular Neurosyphilis can present during any stage
• Syphilis can affect any part of the eye itself and can cause range of
symptoms, including eye pain, vision loss, photopsia, Argyll
Robertson pupil, eye pressure, photophobia. Uveitis is most
common ocular manifestation.
• Ischemic optic neuropathy can occur as part of ocular neurosyphilis
• Persons with CNS involvement can present with symptoms of meningitis,
encephalitis, dementia, stroke, altered mental status, cranial nerve
findings, auditory or ocular defects, tabes dorsalis, and paresis.
• HIV infection is a major risk factor for syphilis infection.
• Rate of HIV co-infection with syphilis ranges between 20-70%.
• Patients with HIV and syphilis co-infection are at higher risk of
developing neurosyphilis.
Therapy
• Parenteral Penicillin G is preferred for all patients with syphilis
• Refer to CDC Guidelines for which Penicillin G formulation (i.e.,
benzathine, aqueous procaine, aqueous crystalline) is appropriate for
each stage of syphilis infection
Neurosyphilis:
• Aqueous crystalline Penicillin G 18-24 million units per day (3-4 million
units IV every 4 hours or continuous infusion for 10-14 days)
• OR Procaine penicillin G 2.4 million units IM once daily + Probenecid
500mg PO 4 times daily for 10-14 days
• Adjunctive steroid treatment is thought to improve optic nerve function
and prevent Jarisch-Herxheimer reaction but needs more data to
support its routine use.

References
•
•
•
•
•
•
•

Centers for Disease Control Sexually Transmitted Diseases Online Resource: 2015 Sexually Transmitted Diseases Treatment
Guidelines. Accessed March 2020.
DynaMed [Internet]. Ipswich (MA): EBSCO Information Services. 1995 - . Record No. T115794, Neurosyphilis; [updated 2018
Nov 30, cited 2020 Mar 23]. Available from https://www-dynamed-com.ezproxy.library.tufts.edu/topics/dmp~AN~T115794.
Parthopratim Dutta Majumder, Elizabeth J. Chen, Janika Shah, Dawn Ching, Wen Ho, Jyotirmay Biswas, Leo See Yin, Vishali
Gupta, Carlos Pavesio & Rupesh Agrawal. Ocular Syphilis: An Update. Ocular Immunology and Inflammation 2019; 27:1, 117125, DOI:10.1080/09273948.2017.1371765
Kelly Meehan and Julie Rodman. Ocular Perineuritis Secondary to Neurosyphilis. Optometry and Vision Science 2010; 87:10,
E790-E796, DOI:10.1097/OPX.0b013e3181f361b0
Ameeta E. Singh. Ocular and neurosyphilis: epidemiology and approach to management. Current Opinion in Infectious
Diseases 2020; 33:1, 66-72, DOI:10.1097/QCO.0000000000000617
UptoDate. Neurosyphilis. Accessed March 2020.
Christina M. Marra. Neurosyphilis. Continuum (Minneap Minn) 2015; 21(6):1714-1728. DOI:10.1212/CON.0000000000000250.
2

et al.: American College of Physicians Posters, Maine Chapter - 2020

Micronutrient Deficiency in IBD; An Underappreciated Complication
Eliott Morgan, M.D. PGY-3
Internal Medicine-Pediatrics Residency, Maine Medical Center, Portland, ME

Case Description

Laboratory Data

History of Present Illness:
PR is 61-year-old female with history of endometrial cancer
status post hysterectomy, ulcerative colitis recently started on
Entyvio, and traumatic splenectomy who presented to Maine
Medical Center with six month of weakness, failure to thrive,
diarrhea, and weight loss.
She reported ongoing poor oral intake and had lost 60lbs over
that six-month period. She described a several-week history of
watery, nonbloody/nonmelanous diarrhea with intermittent
nausea and cramping, but no profound abdominal pain. She
also reported some exertional fatigue, tiring after climbing
three flights of stairs. She also admitted to emotional
challenges after the passing of her mother five months prior to
admission.
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Calcium 7.2
Mg 1.5
Phos 2.4

Micronutrient Pathophysiology

Symptoms

B1 (thiamine) Unclear

Peripheral Neuropathy CD: 32%
Cardiomyopathy
UC: Unknown

MCV 97.1

Protein 5.0
Albumin 1.8
Bilirubin 1.2
AST 8
ALT 21
Alk Phos 92
INR 1.4
CRP: 100.1
ESR: 1

Hospital Course

Micronutrient Deficiencies

Calprotectin 296
C diff: negative
Stool cx: negative
Stool O&P: negative
TTG Ab:1.2
FOBT: positive

Vit D: 33
Vit B12: 1239
Iron 55
Vit A 5.2 (32-78)
Vit E 7.7 (5.5-17)
Vit C <0.1 (0.4-2.0)
Copper 334 (810-1990)
Zinc 33 (60-130)

B9 (folate)

Poor Intake
Megaloblastic Anemia
Malabsorption
Atrophic Glossitis
Medications (MTX, Stomatitis
Depression
Sulfasalazine)

B12

Ileitis
Ileal Resection

C

Poor Intake

Megaloblastic Anemia
Pancytopenia
Peripheral Neuropathy
Dementia
Poor Wound Healing
Gingivitis
Scaly Skin
Arthralgias

Prevalence

CD: 0-26%

CD: 11-22%
> 60cm ileal resection:
100%
20-40cm resection: 48%

CD: > 50%

• Patient was well-appearing on admission, but quickly
deteriorated over her two-week course
• Infectious etiologies were ruled out
• Colonoscopies showed mild to moderate colitis, patient
remained on IV steroids
• Due to initial concerns for food aversion and depression,
enteral feeds were held for fear of insurance coverage
• Labs ultimately revealed severe macro- and micronutrient
deficiencies, enteral feeds were initiated but poorly tolerated
• Patient suffered nutritional hypoglycemia requiring dextrose
fluids
• Patient had ongoing pancytopenia leading to bone marrow
biopsy which showed no evidence of malignancy
• Prior to TPN initiation, the patient suffered a small bowel
perforation  shock  transition to comfort care
Clinical Implications

Social History
Lives in Rangeley, ME with husband. No children
No tobacco or EtOH use
Occasional marijuana, 3-4x/week

Medications
Vedolizumab
Prednisone
Dicyclomine
Ondansetron
Mirtazapine
Potassium Chloride
Physical Exam:
BP 98/66 | HR 104 | T 36.9 °C | Resp 16 | Wt 58.7 kg | SpO2
100% |
General: Awake, alert, oriented. No distress. Lying in stretcher
Eyes: No scleral icterus. No conjunctival injection
HENT: Dry membranes moist. No oral lesions. Normocephalic,
atraumatic.
Neck: No lymphadenopathy or masses. No nuchal rigidity.
Cardiovascular: Regular rhythm, tachycardic. No murmurs. 2+ pulses
Pulm: No accessory muscle use. Clear to auscultation bilaterally with
good air entry.
GI: Non-distended. Normoactive bowel sounds. Soft, non-tender. No
guarding, rebound or rigidity
Musculoskeletal: Full painless range of motion. No joint swelling or
erythema.
Neurological: Cranial nerves II-XII intact. No focal deficits.
Skin: No rashes or lesions. Trace peripheral edema
Psych: attention normal, thoughts organized, short term memory intact

Published by MaineHealth Knowledge Connection, 2021

A

Poor Intake
Poor Wound Healing
Fat Malabsorption Night Blindness
Bile Salt Deficiency Xeropthalmia

IBD: 0-44%

E

Neuropathy
Fat Malabsorption Retinopathy
Bile Salt Deficiency Anemia

Unknown

Colonoscopy

Endoscopic Findings
erythema of
• Mild
terminal ileum
• Pseudopolyposis
throughout ascending,
transverse, and
descending colon
mucosa
• Intervening
without erythema,
ulceration
evidence of active
• No
colitis
of rectum and
• Sparing
rectosigmoid colon
Pathology
Ileum: Focal
• Terminal
active ileitis with
villous atrophy
• Ascending/Transverse
Colon: mild/moderate
chronic active colitis
with cryptitis and crypt
abscess formation
colon:
• Descending
Chronic inactive colitis
• Rectum/Sigmoid:
Chronic inactive colitis

D

K

Poor Intake
Fat Malabsorption
Decreased Sun
Osteopenia
Abnormal Bone
Metabolism
Bleeding
Poor Intake
Fat Malabsorption Cartilage/arterial
Bile Salt Deficiency calcification

CD: 22-70%
UC: 45%

Unknown
CD > UC

Decreased Bone Density
Hypoparathyroidism
Hypertension
Muscle Cramps
Prolonged QTc
IBD: 80-86%
Bone Health
Hypocalcemia
Unclear

Magnesium

Vitamin D
Deficiency
Hypomagnesemia
Poor Intake
Steroid Use
Poor Intake
Diarrheal Losses

Iron

Chronic Blood Loss Microcytic Anemia
Fatigue
Poor Intake
Glossitis
Impaired Iron
Restless Leg Syndrome IBD: 36-90%
Metabolism

Zinc

Poor Wound Healing
Chronic Diarrhea Acrodermatitis
Malabsorption
Poor Taste

Calcium

Selenium
Copper

Post-TPN
Malabsorption
Zinc Ingestion

Unclear

Cardiomyopathy
Cartilage Degeneration Unknown
Hypothyroidism
Low in both UC/CD
Neuropathy
Pancytopenia
Unknown

Given ileal findings on colonoscopy, profound malnutrition,
and small bowel inflammation/fistula on CT, Crohn’s disease
was the most likely etiology despite her previous diagnosis of
ulcerative colitis. There are no definitive studies linking
micronutrient deficiencies to bowel perforation, but anemia
due to iron deficiency has been shown to worsen
malabsorption, vitamin D supplementation has been shown to
decrease hospitalizations, and vitamin B12 deficiency may
increase the likelihood of surgery in Crohn’s patients [3,6].
While unrecognized small bowel disease and glucocorticoid
use likely lead to this patient’s bowel perforation, it remains
possible that nutritional deficiencies also contributed towards
bowel thinning and eventual perforation. Although enteral
nutrition was previously thought inferior to steroids in the
treatment of adult Crohn’s disease, recent evidence shows
similar remission rates among the two therapies. Therefore, in
addition to current biologic agents, early enteral nutrition
should be considered as a means of targeting both
inflammation and malnutrition in Crohn’s disease. [4]
References
1. Hwang C, Ross V, Mahadevan U. Micronutrient deficiencies in inflammatory bowel disease: from A to zinc.
Inflamm Bowel Dis. 2012 Oct;18(10):1961-81.
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Atrial Mass: Case Presentation of Primary Cardiac Neoplasm
1
1
1
1
Pasquale Marotta , DO, Jessica Kvasic , MD, Robert Christman , MD, Sanjeev Francis , MD
1
Maine Medical Center, Portland, ME
Introduction

Case Description

Discussion

• The occurrence of a primary cardiac
malignancy is exceptionally rare.
• Of these, angiosarcoma is the most
commonly seen histological subtype,
known well for its’ invasive behavior.1
• Overall, a diagnosis of cardiac
angiosarcoma carries with it a poor
prognosis.
• However, there have been tremendous
advances made in the ability to view and
distinguish tumors.

• 89-year-old male with atrial fibrillation on apixaban, aortic
stenosis with recent transcatheter aortic valve replacement
(TAVR) (01/2020), prior embolic stroke (04/2020),
hypothyroidism, BPH presenting June 2020 found to have a
Streptococcus bovis bacteremia.
• In the setting of bacteremia, evaluation for endocarditis was
pursued with echocardiography.
• An initial Transthoracic echocardiogram (TTE) was
unremarkable, with subsequent Transesophageal
echocardiogram (TEE) demonstrating a large left atrial mass.
• A cardiac MRI confirmed a large lobulated mass in the left
atrium which extended into the left lower lobe pulmonary vein.
• Cardiology consult did not recommend a cardiac biopsy due to it
being a high risk procedure.
• Staging CT of the chest, abdomen, and pelvis was obtained with
metastatic disease in lower pole of the left kidney well as
multiple nodules in the left lower lobe.
• CT-guided biopsy of the left renal mass confirmed malignant
spindle cell neoplasm, consistent with high-grade sarcoma.

• Angiosarcomas are known for their rapidly progressive nature.2
• Recent TAVR in January 2020, at which time no atrial mass was
present indicating tumor advancement in sheer months.
• TEE has been known for superior image resolution with better
visualization of posterior cardiac structures. 3
• Cardiac MRI aids in distinguishing between thrombi and tumors
within cardiac chambers.4
• This case further necessitates the utility of a multimodal
approach to non-invasively characterize a cardiac mass, which
has been instrumental in achieving an earlier diagnosis of
cardiac angiosarcoma.
• Due to advanced stage at diagnosis and aggressive course of
disease,1 complete surgical resection has been challenging.
• Furthermore, the exact benefit of adjunctive chemotherapy
and/or radiation is still unknown.
• Nonetheless, until further research into angiosarcoma mutations
and potential target drugs are identified, prognosis remains poor.

Image 3 (left):
Contrast image performed via
TEE shows vascularity within
intra-atrial mass.

Image 1:
Apical 4 chamber view TTE with no apparent atrial
or ventricular masses noted.

Image 4 (right):
Cardiac MR (axial view) shows large
lobulated mass (6.7 x 5 x 4.8 cm)
lesion centered within left atrium,
extending into left lower lobe
pulmonary vein with probable
occlusion. Demonstrates
heterogeneous enhancement after
administration of gadolinium.
Image 2:
Mid esophageal 2 chamber view TEE clearly
delineates a large left atrial mass.
https://knowledgeconnection.mainehealth.org/jmmc/vol3/iss1/14
DOI: 10.46804/2641-2225.1080

Discussion (continued)

Image 5 (top):
Low power view demonstrating densely
cellular neoplasm.
Image 6 (bottom):
High power view showing polygonal and
spindle tumor cells with slit-like channels
and extravasated red cells.

Image 7:
CD31 immunohistochemistry with cytoplasmic and
membrane staining of tumor cells.
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Multisystem Inflammatory Syndrome Associated with SARS-CoV-2 Infection,
More Than a Pediatric Syndrome
Ian Milligan, MD – MMC Department of Internal Medicine
et al.: American College of Physicians Posters, Maine Chapter - 2020

Patricia Stogsdill, MD – MMP Department of Adult Infectious Diseases

Case Description

Data

Patient: 27-year-old previously healthy African female
Symptoms:
Five days of rigors, diarrhea, diffuse maculopapular rash, and oliguria.

COVID testing:
consecutive COVID nasal swab PCR tests were collected over a three-day
• Three
period and returned negative.
• Subsequent antibody testing did return grossly positive for COVID IgG 11 days
after the start of her symptoms.

Physical exam:
Fatigued, ill-appearing, tachycardic, abdomen diffusely tender,
maculopapular rash on the medial sections of the extremities.

Imaging:
Echocardiogram showed mild to moderate global hypokinesis, left ventricular
• ejection
fraction 40-45%, mildly dilated right ventricle, mild tricuspid regurgitation,
and pericardial effusion.
• CT chest showed bilateral patchy ground-glass opacities and small bilateral
pleural effusions.
• CT abdomen/pelvis with small ascites

Vitals:
BP 84/52 | HR 111 | Temp 36.7 °C (98 °F) (Oral) | RR 27 | SpO2 97%
Labs:
Absolute lymphocytes 420 cells/uL, creatinine 5.6 mg/dL, troponin I 0.43
ng/mL
Inflammatory markers: ESR 33 mm/hr, CRP 344 mg/L, D-dimer 2818 ng/mL,
ferritin 1082 ng/mL

Treatment Course
•
•
•
•
•
•
•

Patient was transferred to the COVID ICU in the setting of mixed
hypovolemic, vasoplegic, and cardiogenic shock.
She was given vasopressors, heparin for anticoagulation, and later
stress dose corticosteroids.
A course of empiric broad-spectrum antibiotics was completed despite
culture data not elucidating a bacterial source.
Testing for viral and bacterial infections, as well as rheumatologic and
malignant causes was negative.
The patient slowly improved with supportive care. Suspicion returned
to COVID as other causes were eliminated.
Remdesivir, tocilizumab, and convalescent plasma were not given as
COVID testing had been negative while she was inpatient.
Disposition: 7 days in the ICU and 13 days total in the hospital before
discharging home.

Key Points
•
•

•

This case highlights that MIS can occur in
adults.
Further studies are needed to determine the
following for MIS:
• Pathophysiology
(PCR positive or negative)
• Prevalence
of diagnostic criteria
• Accuracy
(steroids, IL-6 inhibitors, etc.)
•We Treatment
hope that this case will raise clinician
awareness of MIS-A and, by doing so, impact
outcomes.
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Multisystem Inflammatory
Syndrome in U.S. Children and
Adolescents (MIS-C)
NEJM article, 186 cases of MIS-C from 26
states in three months.

Case Series of Multisystem Inflammatory
Syndrome in Adults with SARS-CoV-2
Infection – UK and US, March-August 2020
CDC Case Series of 27 patients suspected to have MIS-A

MIS-C Diagnostic Criteria:
• Hospitalization
21 years old
• <Fever
for > 24 hours
• Lab evidence
of inflammation
• Evidence of SARS-CoV-2
Infection
• Multisystem organ involvement:
•
(92%)
• GI
(80%)
• Cardiovascular
(76%)
• Hematologic
(74%)
• Mucocutaneous
Respiratory (70%)
•
14/186 patients developed MIS-C an average
of 25 days after COVID symptom onset.

MIS-A Diagnostic Criteria:
• Hospitalization
years old
• >Lab20evidence
of inflammation
• Evidence of SARS-CoV-2
Infection within 12 weeks
• Absence of severe respiratory
illness
• One or more severe extrapulmonary
organ involvement:
•
• GI
• Cardiovascular
• Hematologic
• Mucocutaneous

Treatment (No efficacy data):
steroids, IL-6 inhibitors (tocilizumab),
• IVIg,
anticoagulation

Treatment (No efficacy data):
• IVIg, steroids, IL-6 inhibitors (tocilizumab), anticoagulation

Patients developed MIS-A an average of 2-5 weeks after COVID
symptom onset. 8/27 had no preceding COVID symptoms.

The authors have no financial disclosures.
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Dreading the Worst: Osmotic demyelination syndrome secondary to rapid correction of hyponatremia
Amjad Mehboob, MBBS
Internal Medicine Residency, Maine Medical Center, Portland, ME.

Introduction
This case reflects the gravity with which perturbations in
extracellular [Na+] and their subsequent correction must
be approached especially in patients who are at high
risk for developing Osmotic demyelination syndrome
(ODS).

Case Presentation





52 years old gentleman with Hx of HTN, alcohol use
presents to ED with worsening dysphagia and
altered mental status.
Recent hospitalization(8 days ago) for hyponatremia
in setting of alcohol use and being on diuretics. He
presented at that time with slurred speech and
altered mental status. CT and MRI head were
unremarkable. SNa was 116 mEq/L on admission. K
was 2.2. LFT’s were moderately deranged. Serum
osmolality was 230.Urine Na was 11 and osmolality
was 500 mOsm/L.TSH and cortisol were normal. He
was treated with 1L of LR and NS which
subsequently dropped his SNa to 101 mEq/L. He
was then treated with continuous 3% hypertonic
saline infusion. Over the next 24 hours his serum
sodium was corrected to 117 mEq/L. Serum Na then
gradually increased to of 131 mEq/L by the time of
discharge two days later. He continued to have
intermittent confusion during hospitalization but
remained without focal neurological deficits. He was
eventually discharged to home after a repeat MR of
the brain was unremarkable
Home Medications:
 Hydrochlorothiazide -lisinopril 12.5mg-20mg,
2tab daily, Metoprolol succ 200mg daily

Physical exam and Labs

Discussion

Physical Exam:
Vitals: BP 112/78 | Pulse 84 | Temp 37.6 °C (99.7 °F) (Axillary) | Resp 17 | Ht 1.829 m (6') | Wt 103.8 kg
(228 lb 13.4 oz) | SpO2 97% | BMI 31.04 kg/m²
Neuro exam:
Does not follow commands. Does not attempt to speak :Cranial nerves: II-XII Intact. Motor: Brisk withdrawal
of both legs with plantar stimulation. Mild withdrawal of both arms with noxious stimulation: Reflexes: 5+ beats
of clonus at the right ankle, sustained clonus at the left ankle, Sensory: Grimaces to noxious stimulation in all
extremities. Coordination: No observed intentional movements from which to judge coordination. Gait: Unable
to walk secondary to altered mental status.
Labs: CBC: Normal: BMP: Normal. AST:45 U/L, ALT: 76 U/L, Bili: Normal, Ammonia: 29
MRI Brain: Hyperintensity in the pons, putamen ,caudate and thalamus bilaterally concerning for ODS.



Osmotic Demyelination syndrome (ODS) refers to central pontine
myelinolysis and extra pontine myelinolysis. The typical clinical
course is biphasic. Initially the patient may present with
encephalopathic features or seizures due to hyponatremia. As
normal sodium concentrations are restored, clinical improvement
initially occurs. In the next few days, the patient's condition
deteriorates, with flaccid paralysis of all 4 limbs and inability to
chew, swallow, or speak. Some patients are left in a state of
mutism and paralysis with relatively intact sensation and
comprehension (termed pseudo coma or locked-in syndrome.



High risk patients for ODS are: Severe hyponatremia (SNa
<120),chronic alcohol use, malnutrition, prolonged diuretic use,
hypokalemia, and liver disease



Recent American guidelines target replacement rates of 4–6 or
4–8 mmol/L/day in patients at high or low risk for ODS,
respectively.



Treatment of severe hyponatremia with hypertonic saline is
necessary and indicated for patients who present with severe
neurologic symptoms however the rate of correction should not
exceed 6-8 mEq/L and continuous infusion of hypertonic saline
should be avoided.



Reversing rapid correction of hyponatremia with desmopressin
and/or hypotonic fluids in osmotic demyelination animal models
has been shown to reduce mortality, but data in humans are
limited



Once ODS develops, treatment options are IVIG, High dose
steroids and plasmapheresis. The outcome is variable with these
treatment modalities.

Hospital Course
He was admitted to the hospital and due to his neurologic and MR findings concerning for ODS, was treated
with 5 sessions of plasmapheresis. His neurological deficits eventually progressed to “locked in” syndrome
and repeat MRI showed worsening of the demyelinating lesions. His family made the decision to pursue
comfort directed care and he ultimately passed away.

Conclusions

Normal MRI Brain

Pons hyperintensity signal

Basal Ganglia hyperintensity signal

It is important to identify patients at high risk for osmotic
demyelination syndrome and to correct their hyponatremia
appropriately.

References
•

•
•
https://knowledgeconnection.mainehealth.org/jmmc/vol3/iss1/14
DOI: 10.46804/2641-2225.1080

.

Vu T, Wong R, Hamblin PS, Zajac J, Patients presenting with severe hypotonic hyponatremia: Etiological factors, assessment,
and outcomes. Hosp Pract (1995) 37: 128–136, 2009
Sterns RH, Nigwekar SU, The treatment of hyponatremia. Semin Nephrol 29: 282–299, 2009
Verbalis JG, Goldsmith SR, Greenberg A, Korzelius C, Schrier RW, Sterns RH, Thompson CJ. Diagnosis, evaluation, and
treatment of hyponatremia: expert panel recommendations. Am J Med 2013;126:S1–42.
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Peri-Operative Diagnosis of Isolated CNS Echinococcus
Presenting as Seizure and Headache
Nicole Rebusi MD1 and Sophie Woolston MD2
Maine Medical Center, Portland, ME
Department of Internal Medicine1 and Department of Infectious Disease2

Introduction
• Echinococcus is a zoonotic parasitic disease with a unique life cycle (Figure 1) that
can infect humans via fecal-oral transmission.
• Eggs passed into feces become ingested by an intermediate host (livestock or
sometimes, humans) and penetrate into the small intestine, thus migrating to other
systems via blood with development into cysts.
• The greatest prevalence is found in the countries of temperate climate zones.
• In humans, infection primarily presents as cysts that are most commonly found in
the liver (~65%), rarely are those infections observed in other organ systems.
• If left untreated, infected patients are at risk of developing organ dysfunction, as well
as anaphylaxis from cyst rupture.
• Isolated intracerebral cystic echinococcosis lesions are extremely rare and
represent only 1-2% of all cases.

A case of isolate intracerebral echinococcosis
in an adult female in Portland, Maine.
• A 41-year old immuno-competent female from Rwanda with one-year history of
recurrent headache is evaluated in the emergency department for new-onset
grand-mal seizures.
• She denied any contact with animals or recent travel, except for a 10-month trip to
Rwanda two years prior where she recalls that she consumed meat that was
prepared by other people.
• Laboratory findings were unremarkable.
• Physical exam did not reveal any focal neurological deficits.

Imaging

Diagnosis & Management
• The solitary, non-calcified, and anechoic nature of the cystic mass on imaging,
as well as the report of gross inspection in the OR was highly suspicious for
Echinococcus infection versus the more common Neurocysticercocosis.
• Empiric treatment was initiated with oral albendazole 15mg/kg/day for a
minimum of 3 months to cover both organisms.
• Serologic studies were sent and returned positive for Echinococcal IgG
antibodies a week later, confirming the diagnosis of Echinococcus.
• At two-week follow-up, she denied recurrent seizures and successfully resumed
all activities of daily living.
• Follow-up imaging with MRI at 1- and 2-months revealed resolving postsurgical
changes at the site of resection without evidence of recurrence.

Discussion
• Although rare in the United States, this case illustrates the importance of
considering Echinococcus in the differential diagnosis of a cystic brain mass,
especially in areas with large immigrant populations whom have traveled from
countries with increased prevalence of parasitic disease.
• This case illustrates the rare possibility of non-hepatic cystic lesions as the
causal representative finding of Echinococcus infection.
• Early recognition via history and radiologic findings may help guide management
with early induction of anti-helminthic therapy, as well as increased preparedness
to avoid cyst rupture during surgery.

Hospital Course

Figure 1. The life cycle of Echinococcus.

Published by MaineHealth Knowledge Connection, 2021

• Despite a lack of clear preoperative diagnosis, it was decided to proceed with
surgery given the patient’s recurrent seizures and the lesion’s accessible location.
• Intraoperatively, the neurosurgeon was suspicious of a parasitic infection given the
resemblance of the observed mass to a hydatid cyst.
• The cyst was successfully resected however, with accidental rupture.
• The specimen was sent to pathology, with confirmatory identification of dead
larvae, prompting the concern for parasitic infection without clear specific etiology.
• Infectious Disease was consulted for concern for management.

References
• “CDC - Echinococcosis - Biology.” Centers for Disease Control and Prevention,
Centers for Disease Control and Prevention, 16 July 2019,
www.cdc.gov/parasites/echinococcosis/biology.html.
• Moro, Pedro, and Peter M. Schantz. “Echinococcosis: a Review.” International
Journal of Infectious Diseases, vol. 13, no. 2, 2009, pp. 125–133.,
doi:10.1016/j.ijid.2008.03.037.
• Pandey, Sharad, et al. “Cerebral Intraventricular Echinococcosis in an Adult.”
Surgical Neurology International, vol. 6, no. 1, 2015, p. 138., doi:10.4103/21527806.163177.
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How well does the
Surprise Question
Predict 1-year Mortality
for Patients with COPD?
Dana Tripp, BA;1 Jaclyn Janis, BSN, RN, MPH;2
Rebecca Hutchinson, MD, MPH2
1
2

Tufts University School of Medicine
Center for Outcomes Research and Evaluation

Introduction

• COPD is the 4th leading cause of death globally.
• Current prognostic tools are hard to use in the
inpatient setting for COPD.
• The surprise question (SQ) is quick to implement
and has been used in some other diseases as an
effective prognostic tool.
• Objective: To understand how well the SQ
predicts 1-year mortality and prompts advance
care planning (ACP) in acute exacerbation of
COPD.

Methods

• Retrospective observational analysis of patients
admitted to MMC for acute exacerbation of
COPD (2015-2018).
• Inpatient providers were asked the SQ, “Would
you be surprised if this patient died in the
next year?”
• SQ+ response equates, “No, I would not be
surprised”, SQ- “Yes, I would be surprised.”
• We assessed performance of the SQ in predicting
mortality and prompting ACP using test
characteristics and logistic regression.

Journal of Maine Medical Center, Vol. 3 [2021], Iss. 1, Art. 14

The surprise question is
associated with oneyear mortality and
should prompt advance
care planning in
patients with COPD.

Table 1. Test characteristics (95% CI) of the
SQ for predicting 1-year mortality
Sensitivity

0.47 (0.36, 0.58)

Specificity

0.75 (0.70, 0.80)

Positive predictive value

0.35 (0.26, 0.45)

Negative predictive value

0.83 (0.78, 0.88)

Table 2. Receipt of advance care planning
by SQ response
SQ+
SQGoals of care
conversation

27 (25 %)

27 (11 %)

Advance Directive
or POLST completed

39 (36 %)

64 (25 %)

Code status change
from full code

33 (30%)

38 (15%)

Palliative care
consult

33 (31 %)

36 (14 %)

All comparison p < 0.01

Unadjusted and adjusteda associations of
the SQ with 1-year mortality and advance
care planningb

Results
•
•

•

•

•
•

30% of responses were SQ+.
SQ+ patients were older and more likely to
have been admitted multiple times in the
six months prior than SQ- patients.
SQ+ and SQ- patients were otherwise similar
in terms of comorbidity burden and baseline
characteristics.
There were no differences in ICU admission,
intubation, length of stay, code status on
admission, or number of readmissions in six
months by SQ response.
More patients with SQ+ were discharged to a
rehabilitation facility than SQ- patients.
1-year mortality was 22% overall, and for
https://knowledgeconnection.mainehealth.org/jmmc/vol3/iss1/14
SQ+ patients was 35%.

DOI: 10.46804/2641-2225.1080

Adjusted for age, sex, and number of admissions in
prior six months
ACP was considered to have occurred if any of the
following were true: AD or POLST form in chart, GOCC
completed, PC consultation performed, or any change
in code status documented

a

b

Abbreviations: COPD, chronic obstructive pulmonary
disease; SQ, surprise question; MMC, Maine Medical
Center; ACP, advance care planning; CI, confidence
interval; POLST, physician order for life sustaining
treatment
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Does Chronic Immunosuppressive Therapy Lower the Risk of Developing Severe
Disease when Infected with COVID-19?
Kiana Vakil-Gilani DO, MPH; Kenneth O’Rourke MD
Internal Medicine Residency, Maine Medical Center, Portland, ME

Background and Purpose












Individuals susceptible to COVID-19
represent heterogeneous populations.
Risk stratification is critical to target
screening, therapeutic interventions, and
resource allocation.
It is unclear whether rheumatic disease
patients on immunosuppressants are at
higher risk of developing severe COVID19 disease.
Current recommendations are to stop
therapy if infected with COVID-19,
except hydroxychloroquine (HCQ) and
tocilizumab in select circumstances.
Limited and conflicting data warrant
surveillance of patients on chronic
immunosuppressive therapy.
We aim to assess correlation between
various rheumatic diseases, their
therapies, and severity of COVID-19
illness.
Hypothesis: Pre-COVID19
immunosuppression with a direct
anticytokine therapy will correlate with
milder COVID-19 disease severity.

Methods
Descriptive analysis of 3 adult rheumatology
patients on chronic immunosuppressive
therapy in a single rheumatology practice
who were diagnosed with COVID-19 by
nasopharyngeal swab between March and
May of 2020. We retrospectively collected
data presented in Table 1.
Published by MaineHealth Knowledge Connection, 2021

Conclusion

Table 1. Demographics, clinical characteristics, treatment, and outcomes



Demographics

Patient 1

Patient

Patient 3

Treatment and Outcomes

Patient 1

Age

75

78

88

Treatment

None

Sex

M

M

F

Race

Caucasian

Caucasian

Caucasian

Acetaminophen
HCQ, Ceftriaxone,
Azithromycin,
Cefepime, Furosemide

BMI (kg/m2)

26

26.08

19.4

Hx of tobacco use

Yes

No

Yes

Yes

No

No

COVID-19 ds. severity based Severe (CURB-65:4)
on CURB65 score

Mild

Mild

ICU stay

Yes

No

No

Mechanical Ventilation

Yes

No

No

ECMO

No

No

No

Length of ventilation (d)

3

N/A

N/A

Length of ICU stay (d)

6

N/A

N/A

Length of hospital stay (d)

19

0

1

Length of symptomatic ds. (d) 24

21

8

Yes

Yes

Patient 2

Patient 3



Co-Morbidities

ARDS diagnosis
Hypertension

Yes

No

Yes

Hyperlipidemia

Yes

Yes

No

CAD

No

No

Yes

Chronic Kidney Disease

No

No

No

Diabetes

No

No

No

Chronic pulmonary ds.

No

No

No

Home Medications
Anti-coagulation

No

No

Yes

Anti-platelet therapy

No

No

No

ACE-I/ARB

Yes

No

No

Rheumatologic Data
Baseline Disease

PsA

PMR, Seronegative Inflammatory PMR, Sarcoidosis
Arthritis

Disease Activity

Remission

Active

Remission

Immunosuppressive therapy +dose

ADA: 40mg q2wks
MTX: 20mg/wk

MTX: 20mg/wk
Pred: 2mg/d

HCQ: 300mg/d

Full Recovery

Length of therapy

ADA: 13yrs
MTX: 27yrs

MTX: Unknown
Pred: 10yrs

HCQ: 7 months

Abbreviations
ADA: adalimumab; CXR: chest xray; HCQ: hydroxychloroquine; MTX: methotrexate; N/A: not applicable;
ND: not done; PMR: polymyalgia rheumatica; Pred: prednisone; PsA: psoriatic arthritis; UNK: unknown

Was therapy held for COVID-19?

Yes

MTX: Yes
Pred: No

No

Yes

Results








Demographics: 75-88 yrs, Caucasian, similar co-morbidity profile including hx of HTN, HLD, and absence of baseline obesity, pulmonary
disease or diabetes.
Patient 1, a 75 y.o. male with PsA on Adalimumab and Methotrexate developed severe COVID-19 as defined by a CURB-65 score of 4. He
was intubated, treated with HCQ, antibiotics, diuresis, and achieved full recovery after 19 days of hospitalization.
Patient 2, a 78 y.o. male with polymyalgia rheumatica and seronegative inflammatory arthritis on Prednisone and Methotrexate presented
with mild symptoms without known pulmonary manifestations. He was not hospitalized and achieved full recovery after 21 days.
Patient 3, an 88 y.o. female with polymyalgia rheumatica and sarcoidosis on HCQ developed mild symptoms of COVID-19 without
pulmonary manifestations. She was hospitalized for one day and achieved full recovery after 8 days.

Patient 1 with long term monoclonal
antibody and DMARD use, developed
the most severe COVID-19 disease
Patient 1 was also the only subject on an
ACE-I.
Patients 2 and 3 who were on a DMARD
developed mild COVID-19 symptoms
despite presence of sarcoidosis in patient
2.

Discussion
Given limited data, a meaningful statement
cannot be made regarding blunting of
COVID-19 disease severity with
immunosuppressive therapy. We plan to
conduct a year long retrospective chart
review of new COVID-19 patients with
rheumatologic conditions in the state of
Maine. In addition to the data in table 1, we
will ask our rheumatologists to assess the
development of post-COVID neutralizing
antibodies with the knowledge that some
DMARDs can interfere with post-vaccination
development of protective antibodies. We
will then use a multi-variate analysis to
extrapolate which immunosuppressive
therapies were associated with the best
outcomes. We aim to develop a secure database where Maine rheumatologists can
upload de-identified data and facilitate data
collection.
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Communication with “remote” caregivers during the COVID-19 pandemic: Early results of a mixed method study
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Zachary Cost1, BS, Anny Fenton2, PhD, Rebecca N. Hutchinson3,4, MD, MPH
1Tufts

University School of Medicine, Boston, MA
2Division of Population Sciences, Dana-Farber / Harvard Cancer Center, Boston, MA
3Division of Palliative Medicine, Maine Medical Center, Portland, ME
4Center for Outcomes Research and Evaluation, Maine Medical Center, Portland, ME

Introduction

Results

• Hospital visitor restrictions have been prevalent during the
COVID-19 pandemic.
• These restrictions prevent informal caregivers, including
family or friends, from helping their loved ones with
communication and medical decision making. Additionally,
caregivers provide needed emotional support and serve as
advocates for patients.
• The aim of this study is to describe the patterns of
communication between healthcare providers and caregivers
of hospitalized patients with heart failure or cancer who
have been rendered remote by the visitor-restricted period
of the COVID-19 pandemic and to investigate the potential
impact of caregivers being remote on patient care and
outcomes.

• The sample was evenly divided between cancer and heart
failure as the primary admission diagnosis.
• Most of the patients were white (93%), about half were men
(51%) and the median age was 70 years old. The most frequent
caregiver relationship was adult children (n=56), followed by
spouses (n=41).
• 62 (64%) patients had documented communication between
their care team and their caregiver. Among those 62 patients,
communication occurred on just under half of the days the
patient was admitted (44%).
• The primary mode of communication was by telephone with
only 5 patients having documented videoconferencing
communication.
• 53 patients had at least one documented goals of care (GOC)
conversation. Patients whose caregivers were contacted
during their admission were 4.5 times more likely to have a
GOC conversation (OR=4.58, p=0.001).
• 10% of patients visited the emergency department (ED) and
21% of patients were readmitted at least once within 30 days
of discharge. Patients whose caregivers were not contacted
during their admission were almost 5 times more likely to
visit the ED within 30 days of discharge (OR=4.92, p=0.018).
Readmission rates were similar irrespective of caregiver
communication (21% vs 20%, p=0.910). ED visit and readmission
rates are shown in Figure A.

Methods
• 97 adult patients admitted to 6 hospitals in Maine for
oncologic issues or heart failure exacerbations for 3 or more
days between 3/25/20 and 5/30/20 with caregivers were
randomly selected.
• Data were retrospectively collected from the electronic
medical record.
• Statistical association was measured using odds-ratios and
Chi-square difference tests (statistical significance at p value
< 0.05).

https://knowledgeconnection.mainehealth.org/jmmc/vol3/iss1/14
DOI: 10.46804/2641-2225.1080

Figure A

Conclusion & Ongoing Research
During the visitor-restricted period of the COVID-19 pandemic,
lack of caregiver contact during hospital admission was associated
with statistically significantly higher rates of 30-day postdischarge ED visits, but did not affect hospital readmission rates.
We will compare outcomes between this sample and a matched
sample of patients hospitalized prior to the pandemic. We will also
conduct qualitative interviews with 25 patients hospitalized during
the pandemic and their caregivers to understand their experiences;
how these experiences were impacted by the caregiver’s lack of
physical access to the patient and the patients’ care team; and how
care teams successfully involved “remote” caregivers.
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Pre-Discharge Scheduled Follow ups and Readmission Rates
among a Cohort of People Experiencing Homelessness
Robert G. Michaud, MD MPH; Kathleen Fairfield, MD, MPH, DrPH
Deb Rothenberg, MD; Adam Normandin, MD
Maine Medical Center, Tufts University School of Medicine
RESULTS

INTRODUCTION

METHODS
• Retrospective Cohort– Chart Review
• Database Cohort: Anyone with at least 1
encounter with PSLC from January 2017 to
July 2019
• Study Cohort: Inpatient encounter between
January 1, 2018 to December 31, 2018
• Exclusion: Anyone not discharged home or
shelter or street
• Levels of pre-discharge scheduling
• Date Listed
• Instructed
• Provider Only
• No follow up

Missing (1.5%)

100

Date Listed
(58.5%)

80

None Listed (7.5%)
Provider Only (10%)
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1. What is the impact of pre-discharge
scheduled follow up on readmission rates
among the PSLC cohort?
2. What is the impact of pre-discharge
scheduled follow up on kept appointments?
3. What are the characteristics of the PSLC
cohort?
4. What are the rates of readmission?

Pre-Discharge Scheduled Follow Up

Co

RESEARCH QUESTIONS

Cohort Characteristics
120

18
-2
9
30
-3
9
40
-4
9
50
-5
9
>6
0

• 1,215 people experiencing homelessness in
Maine in 2019
• Vulnerable population with unmet healthcare
needs
• Higher rates of self-directed discharge and
readmissions
• PSLC = Preble Street Learning Collaborative
• Discharge planning, such as scheduling
follow ups, may help reduce readmissions

Readmissions
35 0

212 patients (69% males) who experienced 319 hospital encounters
146 (84%) White, 21 (10%) Black/African American, 12 (6%) Other
Outcomes
• No statistical difference in pre-discharge scheduled follow up on
readmission rates
• Higher odds of keeping follow up if one is scheduled (OR 7.3, p<0.01)

30 0
25 0
20 0
15 0
10 0
50
0

14-days (30%)

DISCUSSION
• Limitations: Single site, limited sample size, did not stratify
complexity
• Pre-discharge scheduled follow up appointments more likely for
longer LOS
• Discharge coordination is complex
• Scheduling follow up appointments may increase the odds of
keeping/going to a follow up appointment
• Readmission rates were lower among those who kept or rescheduled
their follow up appointments

Published by MaineHealth Knowledge Connection, 2021

30-days (43%)

90-days (62%)

Odds of readmission if kept follow up
appointment (adjusted for age and sex)
14-day (OR 0.52, 95% CI 0.3 - 0.9, p<0.05)
30-day (OR 0.7, 95% CI 0.46 – 1.16, p>0.05)
90-day (OR 0.6, 95% CI 0.39 – 0.97, p<0.05)
Length of Stay (t = 2.3, p<0.05)
Instructed or Date Listed mean LOS = 11 (SD
15.75)
None Listed or Provider Only mean LOS = 5.9
(SD 11.25)

References: W adhera RK, Choi E, Shen C, Yeh RW , Joynt Maddox KE. Trends, Causes, and Outcomes of Hospitalizations for Homeless Individuals. Med Care. 2019;57(1):21-27. doi:10.1097/MLR.0000000000001015, Salhi BA, W hite MH, Pitts SR, W right DW . Homelessness and Emergency Medicine: A Review of the Literature. Acad Emerg Med. 2018;25(5):577-593. doi:10.1111/acem.13358, Hemphill S, Normandin A, Rothenberg D. Changes in hospital utilization by individuals experiencing homelessness after engaging with interdisciplinary , low-barrier healthcare services in Portland , Maine. J Maine Med Cent. 2020;2(1).
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